VRCDF (Verici Dx) Accounts Payable : $0.66 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Accounts Payable?

Verici Dx's Accounts Payable for the quarter that ended in Jun. 2024 was $0.66 Mil.

Verici Dx's quarterly Accounts Payable declined from Jun. 2023 ($1.03 Mil) to Dec. 2023 ($0.48 Mil) but then increased from Dec. 2023 ($0.48 Mil) to Jun. 2024 ($0.66 Mil).

Verici Dx's annual Accounts Payable increased from Dec. 2021 ($0.16 Mil) to Dec. 2022 ($0.96 Mil) but then declined from Dec. 2022 ($0.96 Mil) to Dec. 2023 ($0.48 Mil).

Verici Dx Accounts Payable Historical Data

The historical data trend for Verici Dx's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Accounts Payable Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Accounts Payable

0.39

0.16

0.96

0.48

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Accounts Payable	Get a 7-Day Free Trial			0.39	0.96	1.03	0.48	0.66

Verici Dx Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Verici Dx Accounts Payable Related Terms

Thank you for viewing the detailed overview of Verici Dx's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines